Home Healthcare Biotechnology Neurological Biomarkers Market

Neurological Biomarkers Market Size, Share & Trends Analysis Report By Type (Genomic, Proteomic, Metabolomic, Imaging, Others), By Applications (Alzheimer's Disease, Parkinson’s Disease, Multiple Sclerosis, Autism Spectrum Disorders, Others), By End-User (Hospitals and Hospital Laboratories, Independent Clinical Diagnostic Centers, Research Organizations and Other) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: June 03, 2026 | Author: Debashree B | Format:
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Neurological Biomarkers Market, By Type 2022-2034 (USD MILLION/ Units)
    1. Genomic
    2. Proteomic
    3. Metabolomic
    4. Imaging
    5. Others
  2. Neurological Biomarkers Market, By Applications 2022-2034 (USD MILLION/ Units)
    1. Alzheimer's Disease
    2. Parkinson’s Disease
    3. Multiple Sclerosis
    4. Autism Spectrum Disorders
    5. Others
  3. Neurological Biomarkers Market, By End-User 2022-2034 (USD MILLION/ Units)
    1. Hospitals and Hospital Laboratories
    2. Independent Clinical Diagnostic Centers
    3. Research Organizations and Other
  4. Regional Neurological Biomarkers Market
    1. North America
      1. North America Neurological Biomarkers Market By Type 2022-2034 (USD MILLION/ Units)
        1. Genomic
        2. Proteomic
        3. Metabolomic
        4. Imaging
        5. Others
      2. North America Neurological Biomarkers Market By Applications 2022-2034 (USD MILLION/ Units)
        1. Alzheimer's Disease
        2. Parkinson’s Disease
        3. Multiple Sclerosis
        4. Autism Spectrum Disorders
        5. Others
      3. North America Neurological Biomarkers Market By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals and Hospital Laboratories
        2. Independent Clinical Diagnostic Centers
        3. Research Organizations and Other
      4. U.S.
        1. Genomic
        2. Proteomic
        3. Metabolomic
        4. Imaging
        5. Others
        6. Alzheimer's Disease
        7. Parkinson’s Disease
        8. Multiple Sclerosis
        9. Autism Spectrum Disorders
        10. Others
        11. Hospitals and Hospital Laboratories
        12. Independent Clinical Diagnostic Centers
        13. Research Organizations and Other
      5. Canada
        1. Genomic
        2. Proteomic
        3. Metabolomic
        4. Imaging
        5. Others
        6. Alzheimer's Disease
        7. Parkinson’s Disease
        8. Multiple Sclerosis
        9. Autism Spectrum Disorders
        10. Others
        11. Hospitals and Hospital Laboratories
        12. Independent Clinical Diagnostic Centers
        13. Research Organizations and Other
    2. Europe
      1. Europe Neurological Biomarkers Market By Type 2022-2034 (USD MILLION/ Units)
        1. Genomic
        2. Proteomic
        3. Metabolomic
        4. Imaging
        5. Others
      2. Europe Neurological Biomarkers Market By Applications 2022-2034 (USD MILLION/ Units)
        1. Alzheimer's Disease
        2. Parkinson’s Disease
        3. Multiple Sclerosis
        4. Autism Spectrum Disorders
        5. Others
      3. Europe Neurological Biomarkers Market By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals and Hospital Laboratories
        2. Independent Clinical Diagnostic Centers
        3. Research Organizations and Other
      4. U.K.
        1. Genomic
        2. Proteomic
        3. Metabolomic
        4. Imaging
        5. Others
        6. Alzheimer's Disease
        7. Parkinson’s Disease
        8. Multiple Sclerosis
        9. Autism Spectrum Disorders
        10. Others
        11. Hospitals and Hospital Laboratories
        12. Independent Clinical Diagnostic Centers
        13. Research Organizations and Other
      5. Germany
        1. Genomic
        2. Proteomic
        3. Metabolomic
        4. Imaging
        5. Others
        6. Alzheimer's Disease
        7. Parkinson’s Disease
        8. Multiple Sclerosis
        9. Autism Spectrum Disorders
        10. Others
        11. Hospitals and Hospital Laboratories
        12. Independent Clinical Diagnostic Centers
        13. Research Organizations and Other
      6. France
        1. Genomic
        2. Proteomic
        3. Metabolomic
        4. Imaging
        5. Others
        6. Alzheimer's Disease
        7. Parkinson’s Disease
        8. Multiple Sclerosis
        9. Autism Spectrum Disorders
        10. Others
        11. Hospitals and Hospital Laboratories
        12. Independent Clinical Diagnostic Centers
        13. Research Organizations and Other
      7. Spain
        1. Genomic
        2. Proteomic
        3. Metabolomic
        4. Imaging
        5. Others
        6. Alzheimer's Disease
        7. Parkinson’s Disease
        8. Multiple Sclerosis
        9. Autism Spectrum Disorders
        10. Others
        11. Hospitals and Hospital Laboratories
        12. Independent Clinical Diagnostic Centers
        13. Research Organizations and Other
      8. Italy
        1. Genomic
        2. Proteomic
        3. Metabolomic
        4. Imaging
        5. Others
        6. Alzheimer's Disease
        7. Parkinson’s Disease
        8. Multiple Sclerosis
        9. Autism Spectrum Disorders
        10. Others
        11. Hospitals and Hospital Laboratories
        12. Independent Clinical Diagnostic Centers
        13. Research Organizations and Other
      9. Russia
        1. Genomic
        2. Proteomic
        3. Metabolomic
        4. Imaging
        5. Others
        6. Alzheimer's Disease
        7. Parkinson’s Disease
        8. Multiple Sclerosis
        9. Autism Spectrum Disorders
        10. Others
        11. Hospitals and Hospital Laboratories
        12. Independent Clinical Diagnostic Centers
        13. Research Organizations and Other
      10. Nordic
        1. Genomic
        2. Proteomic
        3. Metabolomic
        4. Imaging
        5. Others
        6. Alzheimer's Disease
        7. Parkinson’s Disease
        8. Multiple Sclerosis
        9. Autism Spectrum Disorders
        10. Others
        11. Hospitals and Hospital Laboratories
        12. Independent Clinical Diagnostic Centers
        13. Research Organizations and Other
      11. Benelux
        1. Genomic
        2. Proteomic
        3. Metabolomic
        4. Imaging
        5. Others
        6. Alzheimer's Disease
        7. Parkinson’s Disease
        8. Multiple Sclerosis
        9. Autism Spectrum Disorders
        10. Others
        11. Hospitals and Hospital Laboratories
        12. Independent Clinical Diagnostic Centers
        13. Research Organizations and Other
      12. Rest of Europe
        1. Genomic
        2. Proteomic
        3. Metabolomic
        4. Imaging
        5. Others
        6. Alzheimer's Disease
        7. Parkinson’s Disease
        8. Multiple Sclerosis
        9. Autism Spectrum Disorders
        10. Others
        11. Hospitals and Hospital Laboratories
        12. Independent Clinical Diagnostic Centers
        13. Research Organizations and Other
    3. APAC
      1. APAC Neurological Biomarkers Market By Type 2022-2034 (USD MILLION/ Units)
        1. Genomic
        2. Proteomic
        3. Metabolomic
        4. Imaging
        5. Others
      2. APAC Neurological Biomarkers Market By Applications 2022-2034 (USD MILLION/ Units)
        1. Alzheimer's Disease
        2. Parkinson’s Disease
        3. Multiple Sclerosis
        4. Autism Spectrum Disorders
        5. Others
      3. APAC Neurological Biomarkers Market By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals and Hospital Laboratories
        2. Independent Clinical Diagnostic Centers
        3. Research Organizations and Other
      4. China
        1. Genomic
        2. Proteomic
        3. Metabolomic
        4. Imaging
        5. Others
        6. Alzheimer's Disease
        7. Parkinson’s Disease
        8. Multiple Sclerosis
        9. Autism Spectrum Disorders
        10. Others
        11. Hospitals and Hospital Laboratories
        12. Independent Clinical Diagnostic Centers
        13. Research Organizations and Other
      5. Korea
        1. Genomic
        2. Proteomic
        3. Metabolomic
        4. Imaging
        5. Others
        6. Alzheimer's Disease
        7. Parkinson’s Disease
        8. Multiple Sclerosis
        9. Autism Spectrum Disorders
        10. Others
        11. Hospitals and Hospital Laboratories
        12. Independent Clinical Diagnostic Centers
        13. Research Organizations and Other
      6. Japan
        1. Genomic
        2. Proteomic
        3. Metabolomic
        4. Imaging
        5. Others
        6. Alzheimer's Disease
        7. Parkinson’s Disease
        8. Multiple Sclerosis
        9. Autism Spectrum Disorders
        10. Others
        11. Hospitals and Hospital Laboratories
        12. Independent Clinical Diagnostic Centers
        13. Research Organizations and Other
      7. India
        1. Genomic
        2. Proteomic
        3. Metabolomic
        4. Imaging
        5. Others
        6. Alzheimer's Disease
        7. Parkinson’s Disease
        8. Multiple Sclerosis
        9. Autism Spectrum Disorders
        10. Others
        11. Hospitals and Hospital Laboratories
        12. Independent Clinical Diagnostic Centers
        13. Research Organizations and Other
      8. Australia
        1. Genomic
        2. Proteomic
        3. Metabolomic
        4. Imaging
        5. Others
        6. Alzheimer's Disease
        7. Parkinson’s Disease
        8. Multiple Sclerosis
        9. Autism Spectrum Disorders
        10. Others
        11. Hospitals and Hospital Laboratories
        12. Independent Clinical Diagnostic Centers
        13. Research Organizations and Other
      9. Taiwan
        1. Genomic
        2. Proteomic
        3. Metabolomic
        4. Imaging
        5. Others
        6. Alzheimer's Disease
        7. Parkinson’s Disease
        8. Multiple Sclerosis
        9. Autism Spectrum Disorders
        10. Others
        11. Hospitals and Hospital Laboratories
        12. Independent Clinical Diagnostic Centers
        13. Research Organizations and Other
      10. South East Asia
        1. Genomic
        2. Proteomic
        3. Metabolomic
        4. Imaging
        5. Others
        6. Alzheimer's Disease
        7. Parkinson’s Disease
        8. Multiple Sclerosis
        9. Autism Spectrum Disorders
        10. Others
        11. Hospitals and Hospital Laboratories
        12. Independent Clinical Diagnostic Centers
        13. Research Organizations and Other
      11. Rest of Asia-Pacific
        1. Genomic
        2. Proteomic
        3. Metabolomic
        4. Imaging
        5. Others
        6. Alzheimer's Disease
        7. Parkinson’s Disease
        8. Multiple Sclerosis
        9. Autism Spectrum Disorders
        10. Others
        11. Hospitals and Hospital Laboratories
        12. Independent Clinical Diagnostic Centers
        13. Research Organizations and Other
    4. Middle East and Africa
      1. Middle East and Africa Neurological Biomarkers Market By Type 2022-2034 (USD MILLION/ Units)
        1. Genomic
        2. Proteomic
        3. Metabolomic
        4. Imaging
        5. Others
      2. Middle East and Africa Neurological Biomarkers Market By Applications 2022-2034 (USD MILLION/ Units)
        1. Alzheimer's Disease
        2. Parkinson’s Disease
        3. Multiple Sclerosis
        4. Autism Spectrum Disorders
        5. Others
      3. Middle East and Africa Neurological Biomarkers Market By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals and Hospital Laboratories
        2. Independent Clinical Diagnostic Centers
        3. Research Organizations and Other
      4. UAE
        1. Genomic
        2. Proteomic
        3. Metabolomic
        4. Imaging
        5. Others
        6. Alzheimer's Disease
        7. Parkinson’s Disease
        8. Multiple Sclerosis
        9. Autism Spectrum Disorders
        10. Others
        11. Hospitals and Hospital Laboratories
        12. Independent Clinical Diagnostic Centers
        13. Research Organizations and Other
      5. Turkey
        1. Genomic
        2. Proteomic
        3. Metabolomic
        4. Imaging
        5. Others
        6. Alzheimer's Disease
        7. Parkinson’s Disease
        8. Multiple Sclerosis
        9. Autism Spectrum Disorders
        10. Others
        11. Hospitals and Hospital Laboratories
        12. Independent Clinical Diagnostic Centers
        13. Research Organizations and Other
      6. Saudi Arabia
        1. Genomic
        2. Proteomic
        3. Metabolomic
        4. Imaging
        5. Others
        6. Alzheimer's Disease
        7. Parkinson’s Disease
        8. Multiple Sclerosis
        9. Autism Spectrum Disorders
        10. Others
        11. Hospitals and Hospital Laboratories
        12. Independent Clinical Diagnostic Centers
        13. Research Organizations and Other
      7. South Africa
        1. Genomic
        2. Proteomic
        3. Metabolomic
        4. Imaging
        5. Others
        6. Alzheimer's Disease
        7. Parkinson’s Disease
        8. Multiple Sclerosis
        9. Autism Spectrum Disorders
        10. Others
        11. Hospitals and Hospital Laboratories
        12. Independent Clinical Diagnostic Centers
        13. Research Organizations and Other
      8. Egypt
        1. Genomic
        2. Proteomic
        3. Metabolomic
        4. Imaging
        5. Others
        6. Alzheimer's Disease
        7. Parkinson’s Disease
        8. Multiple Sclerosis
        9. Autism Spectrum Disorders
        10. Others
        11. Hospitals and Hospital Laboratories
        12. Independent Clinical Diagnostic Centers
        13. Research Organizations and Other
      9. Nigeria
        1. Genomic
        2. Proteomic
        3. Metabolomic
        4. Imaging
        5. Others
        6. Alzheimer's Disease
        7. Parkinson’s Disease
        8. Multiple Sclerosis
        9. Autism Spectrum Disorders
        10. Others
        11. Hospitals and Hospital Laboratories
        12. Independent Clinical Diagnostic Centers
        13. Research Organizations and Other
      10. Rest of MEA
        1. Genomic
        2. Proteomic
        3. Metabolomic
        4. Imaging
        5. Others
        6. Alzheimer's Disease
        7. Parkinson’s Disease
        8. Multiple Sclerosis
        9. Autism Spectrum Disorders
        10. Others
        11. Hospitals and Hospital Laboratories
        12. Independent Clinical Diagnostic Centers
        13. Research Organizations and Other
    5. LATAM
      1. LATAM Neurological Biomarkers Market By Type 2022-2034 (USD MILLION/ Units)
        1. Genomic
        2. Proteomic
        3. Metabolomic
        4. Imaging
        5. Others
      2. LATAM Neurological Biomarkers Market By Applications 2022-2034 (USD MILLION/ Units)
        1. Alzheimer's Disease
        2. Parkinson’s Disease
        3. Multiple Sclerosis
        4. Autism Spectrum Disorders
        5. Others
      3. LATAM Neurological Biomarkers Market By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals and Hospital Laboratories
        2. Independent Clinical Diagnostic Centers
        3. Research Organizations and Other
      4. Brazil
        1. Genomic
        2. Proteomic
        3. Metabolomic
        4. Imaging
        5. Others
        6. Alzheimer's Disease
        7. Parkinson’s Disease
        8. Multiple Sclerosis
        9. Autism Spectrum Disorders
        10. Others
        11. Hospitals and Hospital Laboratories
        12. Independent Clinical Diagnostic Centers
        13. Research Organizations and Other
      5. Mexico
        1. Genomic
        2. Proteomic
        3. Metabolomic
        4. Imaging
        5. Others
        6. Alzheimer's Disease
        7. Parkinson’s Disease
        8. Multiple Sclerosis
        9. Autism Spectrum Disorders
        10. Others
        11. Hospitals and Hospital Laboratories
        12. Independent Clinical Diagnostic Centers
        13. Research Organizations and Other
      6. Argentina
        1. Genomic
        2. Proteomic
        3. Metabolomic
        4. Imaging
        5. Others
        6. Alzheimer's Disease
        7. Parkinson’s Disease
        8. Multiple Sclerosis
        9. Autism Spectrum Disorders
        10. Others
        11. Hospitals and Hospital Laboratories
        12. Independent Clinical Diagnostic Centers
        13. Research Organizations and Other
      7. Chile
        1. Genomic
        2. Proteomic
        3. Metabolomic
        4. Imaging
        5. Others
        6. Alzheimer's Disease
        7. Parkinson’s Disease
        8. Multiple Sclerosis
        9. Autism Spectrum Disorders
        10. Others
        11. Hospitals and Hospital Laboratories
        12. Independent Clinical Diagnostic Centers
        13. Research Organizations and Other
      8. Colombia
        1. Genomic
        2. Proteomic
        3. Metabolomic
        4. Imaging
        5. Others
        6. Alzheimer's Disease
        7. Parkinson’s Disease
        8. Multiple Sclerosis
        9. Autism Spectrum Disorders
        10. Others
        11. Hospitals and Hospital Laboratories
        12. Independent Clinical Diagnostic Centers
        13. Research Organizations and Other
      9. Rest of LATAM
        1. Genomic
        2. Proteomic
        3. Metabolomic
        4. Imaging
        5. Others
        6. Alzheimer's Disease
        7. Parkinson’s Disease
        8. Multiple Sclerosis
        9. Autism Spectrum Disorders
        10. Others
        11. Hospitals and Hospital Laboratories
        12. Independent Clinical Diagnostic Centers
        13. Research Organizations and Other
Report Details
−
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.